A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine.

Détails

Ressource 1Télécharger: 30723234_BIB_968C606B3D56.pdf (4691.75 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_968C606B3D56
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine.
Périodique
Scientific reports
Auteur⸱e⸱s
Plummer S., Wallace S., Ball G., Lloyd R., Schiapparelli P., Quiñones-Hinojosa A., Hartung T., Pamies D.
ISSN
2045-2322 (Electronic)
ISSN-L
2045-2322
Statut éditorial
Publié
Date de publication
05/02/2019
Peer-reviewed
Oui
Volume
9
Numéro
1
Pages
1407
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30% (P~0.07) and ~80% (P < 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/02/2019 18:15
Dernière modification de la notice
20/09/2020 6:27
Données d'usage